Rigosertib as a radio-sensitizer for concurrent chemo-radiation treatment of cholangiocarcinoma (CCA) : a comparative study in vitro by A. Malacrida et al.
IJAE 
Vo l .  122 ,  n .  1  (Supp lem ent) :  127,  2017
© 2017 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
Rigosertib as a radio-sensitizer for concurrent chemo-
radiation treatment of cholangiocarcinoma (CCA): a 
comparative study in vitro 
Alessio Malacrida1, Silvia Damian2, Luigi Celio2, Vincenzo Mazzaferro3 and Mariarosaria Miloso2 
1 Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
2 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
3 Gastrointestinal and Hepatobilio-Pancreatic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
Italy 
Cholangiocarcinoma (CCA) remains a therapeutic challenge. The small-molecule 
Rigosertib can selectively synchronize cancer cells to G2/M phase improving the effi-
cacy of radiation. In our study, we evaluated in vitro Rigosertib (gifted by Onconova 
Therapeutics Inc) effects on two human CCA cell lines: EGI-1 and TFK-1. Rigosertib 
was compared with Gemcitabine (GEM) and 5-Fluorouracil (5-FU), two antineoplastic 
and radio-sensitizer agents used in the treatment of CCA.
Rigosertib impaired cell viability (evaluated by Tripan-blue vital count) in both 
cell lines in a dose- and time-dependent manner (IC50 of 100nM at 24h). GEM and 
5-FU had a IC50 of 30µM and 7µM after 24h, respectively. Cell migration and invasion 
tests was performed by scratch wound healing and Boyden chamber assay respec-
tively. Rigosertib caused a 50% inhibition of the EGI-1 cell migration (10µM) and 
invasion (100nM), while the inhibitory effects on TFK-1 cells were observed with dos-
es of 100µM and 10µM, respectively. GEM 30µM and 5-FU 7µM had no effect on cell 
migration and invasion. Evaluation of cell cycle by FACS cytometry showed a G2/M 
arrest in both cell lines after Rigosertib 100nM for 24h. Radio-sensitizing test was per-
formed by clonogenic survival assay after irradiation. 24h Rigosertib pre-treatment 
(100nM for EG-1 and 1 µM for TFK-1) when followed by 2, 4 or 6 Gy irradiation, 
reduced survival in both CAA cell lines when compared with radiation alone. The 
Rigosertib radio-sensitizer effect was similar to that seen after GEM or 5-FU 24 pre-
treatment both plus irradiation. However, 48h Rigosertib pre-treatment was more 
effective than radiation alone as well as GEM for 48h.
Our study highlights the preliminary but promising preclinical activity of Rigos-
ertib both as antitumoral and as a radio-sensitizer agent in CCA and provides a back-
ground for further investigations.
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